Literature DB >> 12466789

The physiology of lipoproteins.

Thomas N Tulenko1, Anne E Sumner.   

Abstract

The seminal studies of Brown and Goldstein (Science 1986;232:34-47) coupled with the findings of the Framingham study revolutionized our understanding of the metabolic basis for vascular disease. These studies led to the widespread use of the coronary risk lipid profile, which uses the total cholesterol/high-density lipoprotein (HDL) ratio (or low-density lipoprotein [LDL]/HDL ratio) in predicting risk for vascular disease and as a tool for therapeutic management of patients at risk for vascular disease. However, although these methods are predictive of coronary artery disease (CAD) in general, it is also well known that the extent of occlusive disease and CAD varies greatly between individuals with similar cholesterol and HDL lipid profiles. For this reason, the National Cholesterol Education Program Expert Panel revised these guidelines and now recommends monitoring LDL and HDL cholesterol in the context of coronary heart disease risk factors and "risk equivalents." In addition, more recent findings indicate that specific alterations in individual lipoprotein subclasses may account for the variations in CAD in subjects with similar lipid profiles. For example, a preponderance of small, dense LDL particles correlates with a marked increase in risk for myocardial infarction independent of LDL levels. In particular, the association of small, dense LDL with elevated triglycerides (large, less dense VLDL) and reduced HDL has been defined as the atherogenic lipoprotein profile, and the key metabolic defect driving this profile may be elevated levels of triglycerides, specifically large, less dense VLDL. In an attempt to explain the physiologic basis for lipoprotein variations, this review describes the basic metabolic scheme underlying the traditional view of lipoprotein metabolism and physiology. It then examines the identity and role of the various lipoprotein subfractions in an attempt to distill a working model of how lipoprotein abnormalities might account for vascular disease in general and the metabolic syndrome in particular.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12466789     DOI: 10.1067/mnc.2002.128959

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  55 in total

1.  Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

Authors:  M A Austin; M C King; K M Vranizan; R M Krauss
Journal:  Circulation       Date:  1990-08       Impact factor: 29.690

Review 2.  Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study.

Authors:  W B Kannel; W P Castelli; T Gordon
Journal:  Ann Intern Med       Date:  1979-01       Impact factor: 25.391

Review 3.  Opportunities for the treatment of inflammation in cardiovascular disease.

Authors:  D C Crossman
Journal:  Expert Opin Pharmacother       Date:  2001-11       Impact factor: 3.889

Review 4.  High-density lipoprotein--the clinical implications of recent studies.

Authors:  D J Gordon; B M Rifkind
Journal:  N Engl J Med       Date:  1989-11-09       Impact factor: 91.245

5.  Apolipoprotein B metabolism in homozygous familial hypercholesterolemia.

Authors:  R W James; B Martin; D Pometta; J C Fruchart; P Duriez; P Puchois; J P Farriaux; A Tacquet; T Demant; R J Clegg
Journal:  J Lipid Res       Date:  1989-02       Impact factor: 5.922

6.  Cholesterol flux between cells and high density lipoprotein. Lack of relationship to specific binding of the lipoprotein to the cell surface.

Authors:  J B Karlin; W J Johnson; C R Benedict; G K Chacko; M C Phillips; G H Rothblat
Journal:  J Biol Chem       Date:  1987-09-15       Impact factor: 5.157

7.  Characterization of subfractions of triglyceride-rich lipoproteins separated by gel chromatography from blood plasma of normolipemic and hyperlipemic humans.

Authors:  T Sata; R J Havel; A L Jones
Journal:  J Lipid Res       Date:  1972-11       Impact factor: 5.922

8.  Presence of multiple subpopulations of lipoproteins of intermediate density in normal subjects.

Authors:  T A Musliner; C Giotas; R M Krauss
Journal:  Arteriosclerosis       Date:  1986 Jan-Feb

9.  Low-density lipoprotein subclass patterns and risk of myocardial infarction.

Authors:  M A Austin; J L Breslow; C H Hennekens; J E Buring; W C Willett; R M Krauss
Journal:  JAMA       Date:  1988-10-07       Impact factor: 56.272

10.  High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients.

Authors:  J Johansson; L A Carlson; C Landou; A Hamsten
Journal:  Arterioscler Thromb       Date:  1991 Jan-Feb
View more
  20 in total

1.  Identification of cholesterol crystals in plaques of atherosclerotic mice using hyperspectral CARS imaging.

Authors:  Ryan S Lim; Jeffrey L Suhalim; Shinobu Miyazaki-Anzai; Makoto Miyazaki; Moshe Levi; Eric O Potma; Bruce J Tromberg
Journal:  J Lipid Res       Date:  2011-09-23       Impact factor: 5.922

Review 2.  How does blood glucose control with insulin save lives in intensive care?

Authors:  Greet Van den Berghe
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

3.  Triglyceride blisters in lipid bilayers: implications for lipid droplet biogenesis and the mobile lipid signal in cancer cell membranes.

Authors:  Himanshu Khandelia; Lars Duelund; Kirsi I Pakkanen; John H Ipsen
Journal:  PLoS One       Date:  2010-09-22       Impact factor: 3.240

4.  Lipids including cholesteryl linoleate and cholesteryl arachidonate contribute to the inherent antibacterial activity of human nasal fluid.

Authors:  Thai Q Do; Safiehkhatoon Moshkani; Patricia Castillo; Suda Anunta; Adelina Pogosyan; Annie Cheung; Beth Marbois; Kym F Faull; William Ernst; Su Ming Chiang; Gary Fujii; Catherine F Clarke; Krishna Foster; Edith Porter
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

5.  Comparison of biomarkers of oxidative stress and cardiovascular disease in humans and chimpanzees (Pan troglodytes).

Authors:  Elaine N Videan; Christopher B Heward; Kajal Chowdhury; John Plummer; Yali Su; Richard G Cutler
Journal:  Comp Med       Date:  2009-06       Impact factor: 0.982

Review 6.  Circulatory lipid transport: lipoprotein assembly and function from an evolutionary perspective.

Authors:  Dick J Van der Horst; Sigrid D Roosendaal; Kees W Rodenburg
Journal:  Mol Cell Biochem       Date:  2009-01-08       Impact factor: 3.396

Review 7.  Glucose dysmetabolism and prognosis in critical illness.

Authors:  Chiara Lazzeri; Roberto Tarquini; Francesco Giunta; Gian Franco Gensini
Journal:  Intern Emerg Med       Date:  2008-11-22       Impact factor: 3.397

8.  Vitamin C supplementation lowers serum low-density lipoprotein cholesterol and triglycerides: a meta-analysis of 13 randomized controlled trials.

Authors:  Marc P McRae
Journal:  J Chiropr Med       Date:  2008-06

9.  Comparison of nonfasting and fasting lipoprotein subfractions and size in 15,397 apparently healthy individuals: An analysis from the VITamin D and OmegA-3 TriaL.

Authors:  Zareen M Farukhi; Olga V Demler; Michael P Caulfield; Krishnaji Kulkarni; Jay Wohlgemuth; Michael Cobble; Heike Luttmann-Gibson; Chunying Li; John R Nelson; Nancy R Cook; Julie E Buring; Ronald M Krauss; JoAnn E Manson; Samia Mora
Journal:  J Clin Lipidol       Date:  2020-02-21       Impact factor: 4.766

Review 10.  The blind men 'see' the elephant-the many faces of fatty liver disease.

Authors:  Madhusudana Girija Sanal
Journal:  World J Gastroenterol       Date:  2008-02-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.